TSS
PCVX icon

Two Sigma Securities’s Vaxcyte PCVX Stock Holding History

Two Sigma Securities’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5,025
Closed -$232K – 2059
2025
Q4 		$232K Buy
+5,025
New +$225K 0.03% 780
2025
Q3 		– Sell
-13,590
Closed -$442K – 1864
2025
Q2 		$442K Buy
+13,590
New +$446K 0.05% 484

Other funds holding PCVX

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Securities's PCVX Position: Q1 2026 in Review

Two Sigma Securities sold out of Vaxcyte (PCVX) in Q1 2026, closing a stake of 5,025 shares — an estimated $232K sold.

Two Sigma Securities first reported a position in PCVX in Q2 2025 and held it in 2 quarters. The position peaked at $442K in Q2 2025. 336 funds tracked by Wall St. Rank hold PCVX as of Q1 2026.

  • Two Sigma Securities reported no remaining Vaxcyte position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Securities sold 5,025 Vaxcyte shares in Q1 2026, an estimated $232K.
  • Two Sigma Securities first reported a position in Vaxcyte in Q2 2025 and held it in 2 quarters.
  • Two Sigma Securities's Vaxcyte position peaked at $442K in Q2 2025.
  • 336 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2026.

Based on Two Sigma Securities's 13F filing for Q1 2026, filed 15 May 2026.